ADC Therapeutics ZYNLONTA plus rituximab met primary endpoint in Phase 3 LOTIS-5 trial

ADC Therapeutics announced positive topline data from LOTIS-5 Phase 3 trial showing ZYNLONTA combined with rituximab achieved statistical significance on progression-free survival versus standard immunochemotherapy in relapsed/refractory DLBCL patients. The company plans to file a supplemental BLA with the FDA, though safety concerns including higher serious adverse events and Grade 5 deaths in elderly patients warrant regulatory discussion.